Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and
treat HIV-1 infection. However, viral escape through mutation of the HIV-1 envelope …

Highlights•Broadly neutralizing antibodies are promising for HIV-1 prevention and
therapy.•Newly identified bNAbs reveal novel epitopes and binding modes.•Effective …

Anti-HIV broadly neutralizing antibodies (bnAbs) have revealed vaccine targets on the
virus's envelope (Env) protein and are themselves promising immunotherapies. The efficacy …

An increasing number of broadly neutralizing antibodies (bnAbs) are considered leads for
HIV-1 vaccine development and novel therapeutics. Here, we systematically explored the …

Recently identified broadly neutralizing antibodies (bNAbs) that potently neutralize most HIV-
1 strains are key to potential antibody-based therapeutic approaches to combat HIV/AIDS in …

Passive transfer of antibodies has long been considered a potential treatment modality for
infectious diseases, including HIV. Early efforts to use antibodies to suppress HIV …

HIV-1 broadly neutralizing antibodies (bNAbs) are being explored as passively administered
therapeutic and preventative agents. However, the extensively diversified HIV-1 envelope …

Broadly neutralizing antibodies (bNAbs) against the HIV-1 envelope glycoprotein (Env)
suppress viremia in animal models of HIV-1 and humans. To achieve potent activity without …

The epitopes defined by HIV-1 broadly neutralizing antibodies (bNAbs) are valuable
templates for vaccine design, and studies of the immunological development of these …

The Fc region of HIV-1 Env-specific broadly neutralizing antibodies (bNAbs) is required for
suppressing viraemia, through mechanisms which remain poorly understood. Here, we …